⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INMB News
INmune Bio Inc. Common stock
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
globenewswire.com
INMB
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
globenewswire.com
INMB
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
globenewswire.com
INMB
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
globenewswire.com
INMB
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
globenewswire.com
INMB
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
globenewswire.com
INMB
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
globenewswire.com
INMB
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
globenewswire.com
INMB
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
globenewswire.com
INMB